{
    "organizations": [],
    "uuid": "ffc6707235e5a1cb2c13cd1ba3385cffba72e5f1",
    "author": "",
    "url": "https://www.reuters.com/article/brief-ema-to-review-dupixent-as-potentia/brief-ema-to-review-dupixent-as-potential-treatment-for-inadequately-controlled-moderate-to-severe-asthma-idUSFWN1RG018",
    "ord_in_thread": 0,
    "title": "BRIEF-‍EMA To Review Dupixent As Potential Treatment For Inadequately Controlled Moderate-To Severe Asthma​",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 3 (Reuters) - Regeneron Pharmaceuticals Inc:\n* ‍EMA TO REVIEW DUPIXENT® (DUPILUMAB) AS POTENTIAL TREATMENT FOR INADEQUATELY CONTROLLED MODERATE-TO-SEVERE ASTHMA​\n* ‍EUROPEAN MEDICINES AGENCY (EMA) HAS ACCEPTED FOR REVIEW AN APPLICATION FOR DUPIXENT​ Source text for Eikon: Further company coverage:\n ",
    "published": "2018-04-03T08:06:00.000+03:00",
    "crawled": "2018-04-03T08:42:07.008+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "regeneron",
        "pharmaceutical",
        "inc",
        "review",
        "dupilumab",
        "potential",
        "treatment",
        "inadequately",
        "controlled",
        "medicine",
        "agency",
        "ema",
        "accepted",
        "review",
        "application",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}